Showing results (241-250 of 301) with videos related to

Sort By:
Pageof 31
Pharmaceutical Medicine|January 15, 2020
Evaluation of Physician Knowledge of the Key Safety Information for Aflibercept in Canada: Evaluation of Risk-Minimization MeasuresLaurie J Zografos, Elizabeth Andrews, Dan L Wolin, et al.
Pharmaceutical Medicine|July 11, 2025
Combating Antimicrobial Resistance: Role of Key Stakeholders with Focus on the Pharmaceutical SectorSangeeta Sharma, Maneesh Paul Satyaseela, Ranga Reddy Burri, et al.
Pharmaceutical Medicine|May 29, 2025
Transforming Care in China by Using Public-Private Partnerships to Unlock the Power of Patient-Centered Real-World DataMaigeng Zhou, Feng Sun, Fuzhong Xue, et al.
Pharmaceutical Medicine|September 27, 2025
Development of a Competency Framework for Medical Affairs Professionals in AustralasiaAndrew Weekes, Matthew Britland, Cathey Saha, et al.
Pharmaceutical Medicine|July 12, 2025
Pioneering the Future of Medical Affairs: A Strategic Transformation to Meet the Spanish Healthcare Ecosystem's Evolving TrendsAna Pérez Domínguez, Jorge Marinich, Gema Monteagudo, et al.
Pharmaceutical Medicine|July 16, 2025
Treatment Persistence in Rheumatoid Arthritis Before and After Etanercept Biosimilar Introduction: A Nationwide Australian Real-World StudyChin Hang Yiu, Bella D Ianni, Richard O Day, et al.
Pharmaceutical Medicine|April 11, 2025
Cost and Duration of Clinical Trials in Drug Development by Japanese Pharmaceutical CompaniesNorihiro Okada, Yosuke Takahashi
Pharmaceutical Medicine|May 14, 2025
Association Between Health-Related Quality of Life Measures and Survival Endpoints in Oncology Clinical Trials and in Clinical Decision Making: A Narrative ReviewAnna Amela Valsecchi, Massimo Di Maio
Pharmaceutical Medicine|September 20, 2025
The Utilization, Reimbursement, and Cost of Targeted Therapies for Duchenne Muscular Dystrophy (DMD) in US Medicaid Programs: A Descriptive Trend Analysis from 2017 to 2022Yazeed Ghawaa, Alex C Lin, Jeff Jianfei Guo
Pharmaceutical Medicine|August 8, 2025
A Framework for Considering the Role of the Public Sector in R&D of Health TechnologyJuan Carlos Rejon-Parrilla, David Epstein, Jorge Mestre-Ferrandiz, et al.
Pageof 31